Back to top

Analyst Blog

ImmunoGen, Inc. (IMGN - Snapshot Report) announced positive interim results from an ongoing phase I study (n=34) of SAR566658. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

SAR566658 is being developed for the treatment of ovarian, breast, and other epithelial cancer forms. Data from the study revealed that SAR566658 was generally well tolerated. Moreover, the data showed that SAR566658 was capable of inducing objective responses and sustained stable disease in heavily pre-treated patients suffering from CA6-positive cancer.

ImmunoGen mentioned in its press release that limited adverse events normally associated with cytotoxic chemotherapy was observed during the study. The candidate was evaluated at doses bet 10-240 mg/m2 in this portion of the study for 3 weeks. The recommended dosage was identified as 190. SAR566658 is now being assessed at the recommended dose in the extension phase of the study.

ImmunoGen has an agreement with Sanofi (SNY - Analyst Report) for the development of SAR566658, and the initiation of clinical testing. SAR566658 has been developed using ImmunoGen’s Targeted Antibody Payload (TAP) technology. Two more compounds, SAR3419 and SAR650984, developed through the TAP technology, are currently in clinical trials, also in collaboration with Sanofi.

SAR3419 is currently in a phase II study being developed for the treatment of non-Hodgkin lymphoma. Meanwhile, SAR650984 is currently being developed in a phase I study for the treatment of blood cancer including multiple myeloma.

We are encouraged by ImmunoGen’s association with companies of the likes Sanofi and Eli Lilly and Company (LLY - Analyst Report). The company is expected to ink more deals in the future for further pipeline development.

ImmunoGen presently carries a Zacks Rank #3 (Hold). Meanwhile, stocks such as Actelion Ltd. (ALIOF) look better positioned with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
THE PANTRY… PTRY 21.02 +2.09%
INTEL CP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%